Robotic-assisted Partial Nephrectomy for “Very Small” (&lt;2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort

Carbonara, Umberto; Simone, Giuseppe; Minervini, Andrea; Sundaram, Chandru P.; Larcher, Alessandro; Lee, Jennifer; Checcucci, Enrico; Fiori, Cristian; Patel, Devin; Meagher, Margaret; Crocerossa, Fabio; Veccia, Alessandro; Hampton, Lance J.; Ditonno, Pasquale; Battaglia, Michele; Brassetti, Aldo; Bove, Alfredo Maria; Campi, Riccardo; Carini, Marco; Sulek, Jay; Montorsi, Francesco; Capitanio, Umberto; Eun, Daniel; Porpiglia, Francesco; Derweesh, Ithaar; Autorino, Riccardo

doi:10.1016/j.euf.2020.10.001

Cited by 11 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After fulfilling all the inclusion criteria, 13 studies were identified [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ], and another 17 studies were excluded mainly because follow-up was too short [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ]. All of the studies had an retrospective design except the ones from Furukawa et al [ 16 ] and Beauval et al [ 24 ].…”

Section: Resultsmentioning

confidence: 99%

Robot-Assisted Partial Nephrectomy Mid-Term Oncologic Outcomes: A Systematic Review

Vartolomei

Remzi

Fajković

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Robot-assisted partial nephrectomy (RAPN) is used more and more in present days as a therapy option for surgical treatment of cT1 renal masses. Current guidelines equally recommend open (OPN), laparoscopic (LPN), or robotic partial nephrectomy (PN). The aim of this review was to analyze the most representative RAPN series in terms of reported oncological outcomes. (2) Methods: A systematic search of Webofscience, PUBMED, Clinicaltrials.gov was performed on 1 August 2022. Studies were considered eligible if they: included patients with renal cell carcinoma (RCC) stage T1, were prospective, used randomized clinical trials (RCT) or retrospective studies, had patients undergo RAPN with a minimum follow-up of 48 months. (3) Results: Reported positive surgical margin rates were from 0 to 10.5%. Local recurrence occurred in up to 3.6% of patients. Distant metastases were reported in up to 6.4% of patients. 5-year cancer free survival (CFS) estimates rates ranged from 86.4% to 98.4%. 5-year cancer specific survival (CSS) estimates rates ranged from 90.1% to 100%, and 5-year overall survival (OS) estimates rated ranged from 82.6% to 97.9%. (4) Conclusions: Data coming from retrospective and prospective series shows very good oncologic outcomes after RAPN. Up to now, 10-year survival outcomes were not reported. Taken together, RAPN deliver similar oncologic performance to OPN and LPN.

show abstract

Section: Resultsmentioning

confidence: 99%

Robot-Assisted Partial Nephrectomy Mid-Term Oncologic Outcomes: A Systematic Review

Vartolomei

Remzi

Fajković

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Although no studies have directly addressed this issue, data from large studies from MSKCC and Mayo clinic of >500 patients showed that no metastasis occurring in <2 cm renal tumors 104,105. These studies, however, were contradicted by 2 large studies from the Swedish National Kidney Cancer Registry and multi-institutional data of US and European centers that showed 4% and <1% metastasis in renal tumors of up to 2 cm in size 106,107. Carbonara et al107 described Fuhrman grades 3 (15.9%) and 4 (0.5%) in RCCs <2 cm in size.…”

Section: Renal Epithelial Neoplasm Where Low World Health Organizatio...mentioning

confidence: 99%

“…104,105 These studies, however, were contradicted by 2 large studies from the Swedish National Kidney Cancer Registry and multi-institutional data of US and European centers that showed 4% and <1% metastasis in renal tumors of up to 2 cm in size. 106,107 Carbonara et al 107 described Fuhrman grades 3 (15.9%) and 4 (0.5%) in RCCs <2 cm in size. Because of the small but significantly conflicting findings of malignant capability in <2 cm renal tumors, it is important to require low-grade nuclei to diagnose papillary adenoma.…”

Section: Renal Epithelial Neoplasm Where Low World Health Organizatio...mentioning

confidence: 99%

“…108 In cases being considered for MCRNLMP, the presence of WHO/ISUP grade 3 nuclei or expansile nests with intervening vascular sinusoidal pattern warrants additional sampling as it may represent an extensively cystic CCRCC. 107,109 It is unclear if higher grade nuclei alone in the classic context of a multilocular low-grade lesion with only lesional cells lining cysts qualify for MCRNLMP and will influence its prognosis.…”

Section: Renal Epithelial Neoplasm Where Low World Health Organizatio...mentioning

confidence: 99%

See 1 more Smart Citation

Updates in Grading of Renal Cell Carcinomas Beyond Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma

Paner

Chumbalkar

Montironi

et al. 2022

Advances in Anatomic Pathology

View full text Add to dashboard Cite

The World Health Organization (WHO) recommends grading of clear cell renal cell carcinoma (RCC) and papillary RCC using the WHO/International Society of Urological Pathology (ISUP) grade, which is primarily based on nuclear features. As the spectrum of RCC continues to evolve, with more recently described subtypes in the past decade, literature evidence on grading these subtypes is limited or not available for some tumor types. Herein, we outline a pragmatic approach to the topic of grading RCC, dividing the contemporarily described RCC subtypes into 7 categories based on the potential clinical applicability of grading as a useful prognostic parameter: (1) RCC subtypes that are reasonably validated and recommended for WHO/ISUP grading; (2) RCC subtypes where WHO/ISUP is not applicable; (3) RCC subtypes where WHO/ISUP grading is potentially clinically useful; (4) inherently aggressive RCC subtypes where histologic classification itself confers an aggressive biologic potential; (5) renal epithelial tumors where WHO/ISUP grading provides potentially misleading prognostic implication; (6) renal epithelial neoplasms where low WHO/ISUP grade features are a prerequisite for accurate histologic classification; and (7) renal epithelial neoplasms with no or limited data on grading or incomplete understanding of the biologic potential. Our aim in outlining this approach is 2-fold: (a) identify the gaps in understanding and application of grading in RCC subtypes so that researchers in the field may perform additional studies on the basis of which the important pathologic function of assignment of grade may be recommended to be performed as a meaningful exercise across a wider spectrum of RCC; and (b) to provide guidance in the interim to surgical pathologists in terms of providing clinically useful grading information in RCC based on currently available clinicopathologic information.

show abstract

“…For SRMs, PN remains the gold standard whenever feasible ( 11 ); it yields complete pathological information while preserving renal function and providing similar oncological outcomes when compared to RN ( 12 ). Despite nephron sparing surgery offers a definitive treatment, it carries inherent risks such as potential postoperative surgical complications and potential impact on renal function.…”

mentioning

confidence: 99%

Management of small renal mass: unmet needs and quest for high quality evidence

Licari,

Bologna,

Autorino

2024

Transl Androl Urol

View full text Add to dashboard Cite

Robotic-assisted Partial Nephrectomy for “Very Small” (<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort

Cited by 11 publications

References 32 publications

Robot-Assisted Partial Nephrectomy Mid-Term Oncologic Outcomes: A Systematic Review

Robot-Assisted Partial Nephrectomy Mid-Term Oncologic Outcomes: A Systematic Review

Updates in Grading of Renal Cell Carcinomas Beyond Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma

Management of small renal mass: unmet needs and quest for high quality evidence

Contact Info

Product

Resources

About